Eur Rev Med Pharmacol Sci 2020; 24 (10): 5783-5787

DOI: 10.26355/eurrev_202005_21372

Tocilizumab in the treatment of a critical COVID-19 patient: a case report

L. Wang, X. Peng, Z.-H. Wang, J. Cai, F.-C. Zhou

Department of Neurology, the First Affiliated Hospital of Chongqing Medical University, Chongqing, China. zfc88@126.com


In December 2019, Coronavirus disease 2019 (COVID-19) emerged in Wuhan and rapidly spread throughout China and the rest of the world. COVID-19 is currently a global pandemic. There are cytokine storms in severe COVID-19 patients. Interleukin-6 plays an important role in cytokine storm. Tocilizumab is a blocker of interleukin-6 receptor, which is likely to become an effective drug for patients with severe COVID-19. Here, we reported a case in which tocilizumab was effective for a critical COVID-19 patient.

Free PDF Download

To cite this article

L. Wang, X. Peng, Z.-H. Wang, J. Cai, F.-C. Zhou
Tocilizumab in the treatment of a critical COVID-19 patient: a case report

Eur Rev Med Pharmacol Sci
Year: 2020
Vol. 24 - N. 10
Pages: 5783-5787
DOI: 10.26355/eurrev_202005_21372